Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A congenital vascular malformation in the skin (birthmark) characterized by the presence of dilated capillaries. The affected area of the skin is flat and reddish-purplish in color.
Features include: Nevus flammeus.
GNAQ encodes G protein subunit alpha q (359 aa). Guanine nucleotide-binding proteins (G proteins) function as transducers downstream of G protein-coupled receptors (GPCRs) in numerous signaling cascades. Highest expression in Artery Tibial (54.7 TPM) and Brain Frontal Cortex BA9 (54.1 TPM).
Familial multiple nevi flammei is associated with mutations in the GNAQ gene on chromosome 9.
The GNAQ protein participates in G alpha (q):RGS dissociates to inactive G alpha (q) and RHOA GEFs activate RHOA pathways.
GNAQ is classified as a druggable target (Clinically Actionable, Drug Resistance, and Enzyme categories) with score 4.7.
Genetic testing for GNAQ is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for familial multiple nevi flammei has been reported in the published literature.
7 clinical trials registered, 5 recruiting. Interventions under study include medical devices, drug therapy, and procedural interventions. Pipeline includes 2 PHASE2, 5 NA. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07436611](https://clinicaltrials.gov/study/NCT07436611) |
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 9:33 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Rapamycin Dose-Ranging Efficacy Study in Port Wine Stains
PHASE2 |
AFT Pharmaceuticals, Ltd. |
NOT_YET_RECRUITING |
[NCT07250945](https://clinicaltrials.gov/study/NCT07250945) | AdvaTx Laser Treatment for Vascular Birthmarks | NA | Szeged University | RECRUITING |
[NCT05171894](https://clinicaltrials.gov/study/NCT05171894) | A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT | PHASE2 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | RECRUITING |
[NCT07183644](https://clinicaltrials.gov/study/NCT07183644) | Maximizing Laser Therapy Success for Port-Wine Birthmarks in Pediatric Patients | NA | University of Texas Southwestern Medical Center | RECRUITING |
[NCT07015073](https://clinicaltrials.gov/study/NCT07015073) | Comparative of Sequential Application of Pulsed Dye Laser and Potassium-titanyl-phosphate Laser Treatment for Capillary Malformations Versus Single Application | NA | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | RECRUITING |
104 publications have been identified in PubMed for familial multiple nevi flammei. Kisho has analyzed 82 by research type. Research spans Case Report / Case Series (32%), Review / Meta-Analysis (20%), and Other (10%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 26 | 32% |
Research summaries | 16 | 20% |
Other research | 8 | 10% |
Clinical study results | 8 | 10% |
Laboratory research | 7 | 9% |
Disease patterns and progression | 7 | 9% |
New treatment approaches | 7 | 9% |
Testing and diagnosis research | 3 | 4% |
Wang JY (2026). [PMID: 39986392](https://pubmed.ncbi.nlm.nih.gov/39986392/). *J Am Acad Dermatol*. [Review / Meta-Analysis]
Wu S (2026). [PMID: 41888894](https://pubmed.ncbi.nlm.nih.gov/41888894/). *BMC Med Genomics*. [Gene Therapy / Novel Therapeutics]
Khandelwal A (2026). [PMID: 41930186](https://pubmed.ncbi.nlm.nih.gov/41930186/). *Clin Med Insights Case Rep*. [Case Report / Case Series]
Li Y (2026). [PMID: 41110716](https://pubmed.ncbi.nlm.nih.gov/41110716/). *J Am Acad Dermatol*. [Epidemiology / Natural History]
Singh AK (2026). [PMID: 29083797](https://pubmed.ncbi.nlm.nih.gov/29083797/). *Unknown Journal*. [Other]
Unknown (2026). [PMID: 41937274](https://pubmed.ncbi.nlm.nih.gov/41937274/). *Pediatr Dermatol*. [Other]
Anderson RR (2026). [PMID: 41024425](https://pubmed.ncbi.nlm.nih.gov/41024425/). *J Cutan Pathol*. [Diagnostic / Biomarker]
Kodra N (2026). [PMID: 42078255](https://pubmed.ncbi.nlm.nih.gov/42078255/). *Cureus*. [Case Report / Case Series]
Shajil C (2026). [PMID: 33085401](https://pubmed.ncbi.nlm.nih.gov/33085401/). *Unknown Journal*. [Other]
Li M (2026). [PMID: 41557111](https://pubmed.ncbi.nlm.nih.gov/41557111/). *Dermatol Ther (Heidelb)*. [Review / Meta-Analysis]